KalVista Pharmaceuticals, Inc. (KALV)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 39/100 (MEDIUM), 16.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 31.57% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
- KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
- KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
- Chiesi widens rare disease portfolio with $1.9bn KalVista buyout
- KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped Too
- Top Premarket Gainers
- IBT portfolio manager says KalVista deal signals Biotech 2.0 growth
- A Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price Gains
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for KalVista Pharmaceuticals, Inc..
Full KALV Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.